ADIL

Company Overview — What Does ADIAL PHARMACEUTICALS, INC. Do?

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. ADIAL PHARMACEUTICALS, INC. (ADIL) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Cary J. Claiborne and employs approximately 20 people. With a market capitalization of $2M, ADIL is one of the notable companies in the Healthcare sector.

ADIAL PHARMACEUTICALS, INC. (ADIL) Stock Rating — Reduce (April 2026)

As of April 2026, ADIAL PHARMACEUTICALS, INC. receives a Reduce rating with a composite score of 28.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ADIL ranks #3,436 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ADIAL PHARMACEUTICALS, INC. ranks among stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ADIL Stock Price and 52-Week Range

ADIAL PHARMACEUTICALS, INC. (ADIL) currently trades at $1.55. The stock lost $0.01 (0.6%) in the most recent trading session. The 52-week high for ADIL is $3.67, which means the stock is currently trading -57.8% from its annual peak. The 52-week low is $0.13, putting the stock 1071.6% above its annual trough. Recent trading volume was 48K shares, suggesting relatively thin trading activity.

Is ADIL Overvalued or Undervalued? — Valuation Analysis

ADIAL PHARMACEUTICALS, INC. (ADIL) carries a value factor score of 8/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.44x, versus the sector average of 2.75x.

At current multiples, ADIAL PHARMACEUTICALS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ADIAL PHARMACEUTICALS, INC. Profitability — ROE, Margins, and Quality Score

ADIAL PHARMACEUTICALS, INC. (ADIL) earns a quality factor score of 13/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -154.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -122.5% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ADIL Debt, Balance Sheet, and Financial Health

ADIAL PHARMACEUTICALS, INC. has a debt-to-equity ratio of 26.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.42x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $5M.

ADIL has a beta of 0.87, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for ADIAL PHARMACEUTICALS, INC. is 6/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

ADIAL PHARMACEUTICALS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, ADIAL PHARMACEUTICALS, INC. reported revenue of $0 and earnings per share (EPS) of $-11.93. Net income for the quarter was $-8M. Operating income came in at $-8M.

In FY 2025, ADIAL PHARMACEUTICALS, INC. reported revenue of $0 and earnings per share (EPS) of $-11.93. Net income for the quarter was $-8M. Operating income came in at $-8M.

In Q3 2025, ADIAL PHARMACEUTICALS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.08. Net income for the quarter was $-2M. Operating income came in at $-2M.

In Q2 2025, ADIAL PHARMACEUTICALS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.18. Net income for the quarter was $-2M. Operating income came in at $-2M.

Over the past 8 quarters, ADIAL PHARMACEUTICALS, INC. has experienced revenue contraction from $0 to $0. Investors analyzing ADIL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ADIL Dividend Yield and Income Analysis

ADIAL PHARMACEUTICALS, INC. (ADIL) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ADIL Momentum and Technical Analysis Profile

ADIAL PHARMACEUTICALS, INC. (ADIL) has a momentum factor score of 78/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 12/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ADIL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ADIAL PHARMACEUTICALS, INC. (ADIL) ranks #— out of 838 stocks based on the Blank Capital composite score. This places ADIL in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ADIL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ADIL vs S&P 500 (SPY) comparison to assess how ADIAL PHARMACEUTICALS, INC. stacks up against the broader market across all factor dimensions.

ADIL Next Earnings Date

No upcoming earnings date has been announced for ADIAL PHARMACEUTICALS, INC. (ADIL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ADIL? — Investment Thesis Summary

The quantitative profile for ADIAL PHARMACEUTICALS, INC. suggests caution. The quality score of 13/100 flags below-average profitability. The value score of 8/100 indicates premium valuation. Price momentum is positive at 78/100, suggesting the trend favors buyers. High volatility (stability score 6/100) increases portfolio risk.

In summary, ADIAL PHARMACEUTICALS, INC. (ADIL) earns a Reduce rating with a composite score of 28.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ADIL stock.

Related Resources for ADIL Investors

Explore more research and tools: ADIL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ADIL head-to-head with peers: ADIL vs AZN, ADIL vs SLGL, ADIL vs VMD.